Neurodegenerative diseases.

Protein power

Many NDs have been classified as neurodegenerative proteinopathies over recent decades, as they result in the accumulation of misfolded proteins in the brain. These atypical protein conformations – or amyloids – are thought to be the cause of almost 50 conditions, and are likely shaped by primary amyloid-forming proteins that contribute differentially towards disease prognosis.1 Resolving these protein patterns at the proteoform level – a specific molecular variant of a protein that includes post-translational modifications – could therefore lead to huge advances in how we diagnose and treat these disorders. In the meantime, assays are available to measure many of the proteins thought to be involved in CSF and serum, potentially aiding the diagnosis and management of various conditions.

Alzheimer’s disease (AD)

AD is one of the most common neurodegenerative proteinopathies, and has been the subject of much research since the early nineties, leading to the discovery of specific proteins involved in its pathology. Current theory suggests that patients with AD have lowered amyloid-beta 1-42 (Aβ1-42) and elevated tubulin-associated unit (TAU) levels compared to healthy controls. However, these proteins also play a role in the pathogenesis of other NDs, and additional proteins must be measured in conjunction to improve diagnostic accuracy. For example, increased TAU levels in the brain is are also representative of FTD, but elevated phosphorylated TAU (pTAU) is a hallmark of AD alone, and so measuring both markers can aid differential diagnosis.

Furthermore, measuring Aβ1-42 by itself can produce false positive or negative results, but the ratio of Aβ1-42 to amyloid-beta 1-40 (Aβ1-40) has been shown to be a superior diagnostic marker for AD.2 This can help to distinguish between AD and other dementias, such as vascular dementia, dementia with Lewy bodies and FTD.3 These proteins feature heavily in the latest paper by the International Working Group for AD, which recognizes the diagnosis of AD should be based on both clinical and biological characteristics, recommending Aβ1-42, Aβ1-42:Aβ1-40 ratio and pTAU as favorable biomarkers.4

Neurofilaments

Another set of biomarkers garnering interest for the management of NDs is neurofilament proteins. These are structural components of myelinated axons on neurons, which define the shape and diameter of the axon, as well as playing a crucial role in signal propagation. The neurofilament light chain (NF-L) is a subunit that is especially of interest to the management of many NDs, as its level increases in the CSF and blood in proportion to the degree of axonal damage.5 Being able to identify and quantify axonal damage could help to improve diagnostic and prognostic accuracy for many diseases, including MS and ALS.5

Multiple sclerosis

MS causes demyelination of neurons, leading to axonal degradation that results in the debilitating symptoms suffered by patients. As a result, neurofilaments are released into the CSF, increasing the concentration of NF-L.6 Elevated NF-L levels in CSF could therefore be used as a prognostic marker in MS, both for clinically isolated syndrome – the first bout of MS – and relapsing-remitting MS, as well as for assessing treatment success.7 NF-L also appears in the serum of patients with MS, with multiple studies highlighting the correlation between serum and CSF NF-L levels, indicating that blood sampling could potentially replace CSF testing.6,8

Amyotrophic lateral sclerosis

Similarly, NF-L is found at high levels in both CSF and serum of patients with ALS, and an increasing weight of evidence supports its claim as an accurate biomarker for this condition.9 NF-L levels were found to be significantly higher in patients with the onset of early symptoms, indicating this biomarker has the potential to enhance diagnostic accuracy at first presentation.10 It is also appealing for improving prognostic accuracy, by being able to more closely measure patients’ pharmacodynamic response to treatment.9

With an increasing number of people living with neurodegenerative diseases, innovative methods to improve diagnosis and monitor treatment are essential. The novel biomarkers and assays discussed here provide more information to help distinguish between conditions for patients presenting with similar symptoms, potentially aiding in earlier diagnosis and treatment monitoring.

Measuring neuronal biomarkers in blood.

As CSF has disadvantages in sampling and not all patients do receive a lumbar puncture (e.g. PD, LBD… patients) studies have shown the usefulness of measuring certain biomarkers also in blood.

Boost your blood plasma data.

Easily eliminate inhibiting matrix effects and enrich your target by immunoprecipitation using TECAN’s NEURO IP product portfolio provided by Roboscreen for total TAU, p50Tau, brain-derived TAU, beta-Amyloid, and patho-oligomeric alpha-Synuclein, enhancing the performance of your downstream assay of choice. The downstream analysis can then be any type of assay system, such as the Roche Elecsys®, the Mesoscale QuickPlex, Quanterix SIMOA®, Fujirebio Lumipulse® or even any type of ELISA.

More information

To find out more or to see our full portfolio please visit:

www.ibl-international.com/alzheimer-neuroscience